# Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

> **NCT06939816** · PHASE2 · TERMINATED · sponsor: **Enyo Pharma** · enrollment: 10 (actual)

## Conditions studied

- Chronic Kidney Disease Stage 2
- Chronic Kidney Disease Stage 3
- Metabolic Dysfunction-Associated Steatohepatitis

## Interventions

- **DRUG:** Vonafexor low dose
- **DRUG:** Vonafexor high dose

## Key facts

- **NCT ID:** NCT06939816
- **Lead sponsor:** Enyo Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-07-01
- **Primary completion:** 2025-12-22
- **Final completion:** 2026-03-13
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939816, "Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06939816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*